Patents by Inventor Toru Yoshimura

Toru Yoshimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230176047
    Abstract: Sample analysis systems and methods using assay surfaces, assay processing units (APUs), assay processing systems (APSs), and laboratory systems are disclosed. An assay surface includes a sample processing component comprising a plurality of regions, including at least one wash region and at least one storage region configured to hold a plurality of solid supports moveable through the regions under a magnetic force, and a detection component configured to receive the solid supports. An APU includes an assay surface receiving component, a magnetic element configured to generate a moveable magnetic field, and one or more processors configured to move the magnetic field. An APS includes one or more assay surfaces and an APU. A laboratory system includes one or more APSs and a controller for parallel processing. Sample processing and detection methods are disclosed with a reduced sample volume and/or shortened processing time and/or higher sensitivity.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 8, 2023
    Applicant: ABBOTT LABORATORIES
    Inventors: Toru YOSHIMURA, Yoshiyuki ARAI, Tomotaka KOMORI, Ryotaro CHIBA, Jeffrey HUFF
  • Patent number: 11492658
    Abstract: Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide comprising, in the 5? to 3? direction, a first signal DNA generation sequence, an endonuclease recognition site, and a sequence complementary to the 3? end of a target nucleic acid; a second oligonucleotide comprising, in the 5? to 3? direction, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide; a third oligonucleotide comprising, in the 5? to 3? direction, a third signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the second signal DNA generation sequence of the second oligonucleotide.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: November 8, 2022
    Assignee: ABBOTT LABORATORIES
    Inventors: Makoto Komori, Toru Yoshimura
  • Patent number: 11340229
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 24, 2022
    Assignees: Abbott Japan LLC, The University of Tokyo
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • Publication number: 20220043000
    Abstract: Disclosed herein are methods, kits, and systems relates for detecting the presence or determining the amount of SARS-CoV-2 nucleocapsid protein in one or more samples obtained from a subject.
    Type: Application
    Filed: August 4, 2021
    Publication date: February 10, 2022
    Inventors: A. Scott Muerhoff, Toru Yoshimura, Philip M. Hemken, Eitan Israeli, Ryotaro Chiba, Takamitsu Morikawa, Dong Wang, Fusamitsu Yanagihara
  • Publication number: 20200283822
    Abstract: Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide comprising, in the 5? to 3? direction, a first signal DNA generation sequence, an endonuclease recognition site, and a sequence complementary to the 3? end of a target nucleic acid; a second oligonucleotide comprising, in the 5? to 3? direction, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide; a third oligonucleotide comprising, in the 5? to 3? direction, a third signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the second signal DNA generation sequence of the second oligonucleotide.
    Type: Application
    Filed: March 12, 2020
    Publication date: September 10, 2020
    Inventors: Makoto Komori, Toru Yoshimura
  • Patent number: 10641768
    Abstract: The present disclosure describes methods and kits for reducing interferences in immunoassays performed on solid phase and on samples containing serum or plasma, by adding an effective amount of a polycationic derivative of dextran to the assay.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: May 5, 2020
    Assignee: ABBOTT JAPAN CO. LTD.
    Inventors: Toru Yoshimura, Kenju Fujita
  • Patent number: 10604790
    Abstract: Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide comprising, in the 5? to 3? direction, a first signal DNA generation sequence, an endonuclease recognition site, and a sequence complementary to the 3? end of a target nucleic acid; a second oligonucleotide comprising, in the 5? to 3? direction, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide; a third oligonucleotide comprising, in the 5? to 3? direction, a third signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the second signal DNA generation sequence of the second oligonucleotide.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: March 31, 2020
    Assignee: ABBOTT LABORATORIES
    Inventors: Makoto Komori, Toru Yoshimura
  • Publication number: 20190242899
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • Patent number: 10316353
    Abstract: Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting said sample, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide. Also disclosed are methods for detecting a target nucleic acid in a sample in which said sample is contacted, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide and a signal amplifier oligonucleotide. The disclosure also provides compositions and kits comprising such sequence conversion and signal amplifier oligonucleotides.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: June 11, 2019
    Assignees: Abbott Laboratories, Tokyo Institute of Technology
    Inventors: Ken Komiya, Makoto Komori, Toru Yoshimura
  • Publication number: 20190056385
    Abstract: This present invention relates generally to devices, systems, and methods for performing bioimaging at the microscopic scale and, more particularly, to devices and systems including a disposable testing device configured to perform bioimaging at the microscopic scale, and methods of performing the bioimaging using the disposable testing device. In some aspects, a method is provided for imaging assay beads. The method includes moving a blood sample into a sample testing conduit having a first wall formed from at least a portion of an imager chip, a second wall formed from a transparent material layer, and a plurality of wells. The method further including driving a light emitter to project light through the wells, recording an output signal of at least one of absorbance and fluorescence, and converting the output signal to a value indicative of a reaction of a biological sample within each of the plurality of wells.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Applicant: Abbott Point of Care Inc.
    Inventors: Sergey Gershtein, Matt Bates, David Sabourin, Toru Yoshimura
  • Publication number: 20190056384
    Abstract: This present invention relates generally to devices, systems, and methods for performing bioimaging at the microscopic scale and, more particularly, to devices and systems including a disposable testing device configured to perform bioimaging at the microscopic scale, and methods of performing the bioimaging using the disposable testing device. In some aspects, a testing device is provided for imaging assay beads. The testing device having a sample entry port for receiving the blood sample; a sample testing conduit fluidically connected to the sample entry port, the sample testing conduit including: (i) a planar member, (ii) a transparent planar member, and (iii) a plurality of wells having a predetermined average well height and disposed between the first planar member and the second planar member; and an imager chip forming at least a portion of the planar member.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Applicant: Abbott Point of Care Inc.
    Inventors: Sergey Gershtein, Matt Bates, David Sabourin, Toru Yoshimura
  • Patent number: 10208333
    Abstract: Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting said sample, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide having locked nucleic acids at select positions sufficient to decrease non-specific background signal amplification. Also disclosed are methods for detecting a target nucleic acid in a sample in which said sample is contacted, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide and a signal amplifier oligonucleotide, both having locked nucleic acids at select positions sufficient to decrease non-specific background signal amplification. The disclosure also provides compositions and kits comprising such sequence conversion and signal amplifier oligonucleotides.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: February 19, 2019
    Assignees: Abbott Laboratories, Tokyo Institute of Technology
    Inventors: Ken Komiya, Makoto Komori, Toru Yoshimura
  • Publication number: 20180347001
    Abstract: Disclosed are methods for detecting a target nucleic acid in sample, which include contacting the sample with an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5? to 3? direction, an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to the target nucleic acid; a polymerase; and an endonuclease capable of nicking the endonuclease recognition site. The disclosure also provides compositions and kits comprising an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5? to 3? direction an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to a target nucleic acid.
    Type: Application
    Filed: July 27, 2018
    Publication date: December 6, 2018
    Inventors: KEN KOMIYA, MAKOTO KOMORI, TORU YOSHIMURA
  • Patent number: 10107826
    Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 23, 2018
    Assignee: Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Eisaku Yoshida, Ryotaro Chiba
  • Patent number: 10067124
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 4, 2018
    Assignees: Abbott Laboratories, Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Patent number: 10036077
    Abstract: Disclosed are methods for detecting a target nucleic acid in sample, which include contacting the sample with an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5? to 3? direction, an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to the target nucleic acid; a polymerase; and an endonuclease capable of nicking the endonuclease recognition site. The disclosure also provides compositions and kits comprising an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5? to 3? direction an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to a target nucleic acid.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: July 31, 2018
    Assignees: Abbott Laboratories, Tokyo Institute of Technology
    Inventors: Ken Komiya, Makoto Komori, Toru Yoshimura
  • Publication number: 20170089889
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Application
    Filed: October 3, 2016
    Publication date: March 30, 2017
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Publication number: 20170089905
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 30, 2017
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • Patent number: 9528998
    Abstract: Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 27, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Toru Yoshimura, Ryotaro Chiba
  • Publication number: 20160340710
    Abstract: Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide comprising, in the 5? to 3? direction, a first signal DNA generation sequence, an endonuclease recognition site, and a sequence complementary to the 3? end of a target nucleic acid; a second oligonucleotide comprising, in the 5? to 3? direction, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide; a third oligonucleotide comprising, in the 5? to 3? direction, a third signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the second signal DNA generation sequence of the second oligonucleotide.
    Type: Application
    Filed: December 24, 2015
    Publication date: November 24, 2016
    Inventors: Makoto Komori, Toru Yoshimura